Generation and characterization of four novel monoclonal antibodies against human programmed death-1 molecule

Hybridoma

Volumn 29, Issue 2, 2010, Pages 153-160

  Chen, Yongjing ^a,b   Hu, Zhenhua ^a   Wang, Qin ^a,b   Ge, Yan ^a,b   Bai, Lixiong ^a   Wang, Xuefeng ^a   Zhang, Xueguang ^a,b  

^a SOOCHOW UNIVERSITY   (China)

^b MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1F8; MONOCLONAL ANTIBODY 4B9; MONOCLONAL ANTIBODY 8F5; MONOCLONAL ANTIBODY 9H1; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; LEUKOCYTE ANTIGEN; PDCD1 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BIOTECHNOLOGY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HYBRIDOMA; LYMPHOCYTE PROLIFERATION; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; ANIMAL; ANTIBODY SPECIFICITY; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL LINE; CELL PROLIFERATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; BLOTTING, WESTERN; CELL LINE; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; HYBRIDOMAS; MICE; MICE, INBRED BALB C; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 77952061452     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2009.0091     Document Type: Article

References (35)

1. Lanzavecchia A, Lezzi G, and Viola A: From TCR engagement to T cell activation: a kinetic view of T cell behavior. Cell 1999;96:1-4.
2. Lenschow DJ, Walunas TL, and Bluestone JA: CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996;14:233-258.
3. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, and Riley JL: CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005;25:9543-9553.
4. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, and Murphy KM: BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003;4:670-679.
5. Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, Collins M, Honjo T, Freeman GJ, and Carreno BM: PD-1: PD-L inhibitory pathway affects both CD4 (+) and CD8 (+) T cells and is overcome by IL-2. Eur J Immunol 2002;32:634-643.
6. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA, and Freeman GJ: Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003;170:1257-1266.
7. Kuipers H, Muskens F, Willart M, Hijdra D, van Assema FB, Coyle AJ, Hoogsteden HC, and Lambrecht BN: Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. Eur J Immunol 2006;36:2472-2482.
8. Ishida Y, Agata Y, Shibahara K, and Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11:3887-3895.
9. Chemnitz JM, Parry RV, Nichols KE, June CH, and Riley JL: SHP-1 and SHP-2 associate with immunoreceptor tyrosinebased switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004;173:945-954.
10. Dong H, Zhu G, Tamada K, and Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999;5:1365-1369.
11. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, and Freeman GJ: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001;2:261-268.
12. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V, Bowman MR, Carreno BM, Collins M, Wood CR, and Honjo T: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000;192:1027-1034.
13. Blank C, Brown I, Marks R, Nishimura H, Honjo T, and Gajewski TF: Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J Immunol 2003;171:4574-4581.
14. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, and Sharpe AH: Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006;203:883-895.
15. Zhu B, Guleria I, Khosroshahi A, Chitnis T, Imitola J, Azuma M, Yagita H, Sayegh MH, and Khoury SJ: Differential role of programmed death-ligand 1 and programmed death-ligand 2 in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J Immunol 2006;176:3480-3489.
16. Trabattoni D, Saresella M, Pacei M, Marventano I, Mendozzi L, Rovaris M, Caputo D, Borelli M, and Clerici M: Costimulatory pathways in multiple sclerosis: distinctive expression of PD-1 and PD-L1 in patients with different patterns of disease. J Immunol 2009;183:4984-4993.
17. Dong H, Strome SE, Matteson EL, Moder KG, Flies DB, Zhu G, Tamura H, Driscoll CL, and Chen L: Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest 2003;111:363-370.
18. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, and Chen L: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002;8:793-800.
19. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, and Minato N: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99:12293-12297.
20. Wong RM, Scotland RR, Lau RL, Wang C, Korman AJ, Kast WM, and Weber JS: Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol 2007;19:1223-1234.
21. Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, Yamazaki T, Azuma M, Iwai H, Khoury SJ, Auchincloss H Jr, and Sayegh MH: The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003;198:63-69.
22. Iwai Y, Okazaki T, Nishimura H, Kawasaki A, Yagita H, and Honjo T: Microanatomical localization of PD-1 in human tonsils. Immunol Lett 2002;83:215-220.
23. Godfrey WR, Spoden DJ, Ge YG, Baker SR, Liu B, Levine BL, June CH, Blazar BR, and Porter SB: Cord blood CD4 (+) CD25 (+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 2005;105:750-758.
24. Zhang JY, Zhang Z, Wang X, Fu JL, Yao J, Jiao Y, Chen L, Zhang H, Wei J, Jin L, Shi M, Gao GF, Wu H, and Wang FS: PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 2007;109:4671-4678.
25. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A, and Nagler A: Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14:3044-3051.
26. Qiu YH, Sun ZW, Shi Q, su CH, Chen YJ, Shi YJ, Tao R, Ge Y, and Zhang XG: Apoptosis of multiple myeloma cells induced by agonist monoclonal antibody against human CD28. Cell Immunol 2005;236:154-160.
27. Wang Q, Chen Y, Xie F, Ge Y, Wang X, and Zhang X: A novel agonist anti-human OX40L monoclonal antibody that stimulates T cell proliferation and enhances cytokine secretion. Hybridoma 2009;28:269-276.
28. Watts TH: TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-68.
29. Greenwald RJ, Freeman GJ, and Sharpe AH: The B7 family revisited. Annu Rev Immunol 2005;23:515-548.
30. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, and Fujii S: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007;104:3360-3365.
31. Zhang L, Gajewski TF, and Kline J: PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 2009;114:1545-1552.
32. Okudaira K, Hokari R, Tsuzuki Y, Okada Y, Komoto S, Watanabe C, Kurihara C, Kawaguchi A, Nagao S, Azuma M, Yagita H, and Miura S: Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol 2009;35:741-749.
33. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, and Walker BD: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006;443:350-354.
34. Chen L, Zhang Z, Chen W, Zhang Z, Li Y, Shi M, Zhang J, Chen L, Wang S, and Wang FS: B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J Immunol 2007;178:6634-6641.
35. Dotti G: Blocking PD-1 in cancer immunotherapy. Blood 2009;114:1457-1458.